Phaseline

Companies › Lixte Biotechnology Holdings

Lixte Biotechnology Holdings: clinical trials, targets and expected readouts

1 active drug program in 4 registered trials: 4 Phase 1; Hematology, Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
LB-100
Serine/threonine protein phosphatase 2A, catalytic subunit, alpha isoform inhibitor; Serine/threonine protein phosphatase 2A, catalytic subunit, beta isoform inhibitor; Serine/threonine-protein phosphatase 5 inhibitor
PPP2CA, PPP2CB, PPP5CPhase 1Myelodysplastic Syndromes; Advanced Soft-tissue Sarcoma; Extensive Stage Lung Small Cell Carcinoma; Metastatic Microsatellite-stable Colorectal Cancer–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03886662LB-100Phase 1Myelodysplastic SyndromesHematologyMay 2021
NCT05809830LB-100Phase 1Advanced Soft-tissue SarcomaOncologyJun 2025
NCT04560972LB-100Phase 1Extensive Stage Lung Small Cell CarcinomaOncologyJan 2027
NCT06012734LB-100Phase 1Metastatic Microsatellite-stable Colorectal CancerOncologyJul 2028

Targets

PPP2CA (1) PPP2CB (1) PPP5C (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.